European Journal of Molecular & Clinical Medicine

Background: Vernal keratoconjunctivitis (VKC) is a chronic, bilateral allergic disease
of the external eye that leads to chronic irritation, watering, and discharge. It occurs
universally but is more common in hot and dry environments. It typically affects
children in their first two decades and although the majority of cases have a good
prognosis and This study is undertaken to stress upon the importance of clinical
manifestations, management and prevent the complications of the disease and those
secondary to its long-term medication.Aim of study:To study the clinical features
(ocular symptoms, signs and type), the age and sex distribution, the seasonal variation
of symptoms,and the effect of topical therapy on VKC patients.

Background: Vernal keratoconjunctivitis (VKC) is a chronic recurrent non-infectious
allergic disease that generally affects children and young adults. The present study was
conducted to assess efficacy of topical 0.05% cyclosporine in
Vernalkeratoconjunctivitis.
Materials & Methods: 86 patients diagnosed with Vernalkeratoconjunctivitis (VKC) of
both genderswere enrolled. All were prescribed topical 0.05% cyclosporine 4 times a
day. Patients underwent complete ophthalmic examination and symptoms and signs and
intraocular pressure using rebound tonometer. The patients were evaluated at weeks 4,
8 and 12 after the initiation of therapy. Symptoms and signs before and after treatment,
during the four-week intervals, were recorded and scores between 0 and 3 were
assigned.
Results: Out of 86 patients, males were 56 and females were 30. Median of symptoms
score at baseline was 11, at 4 weeks was 4, at 8 weeks was 5 and at 12 weeks was 4. Sign
score at baseline was 6, at 4 weeks was 4, at 8 weeks was 3 and at 12 weeks was 3. The
difference was significant (P< 0.05).
Conclusion: Topical cyclosporine 0.05% help to reduce corticosteroid usage, is an
effective and safe alternative for the treatment of resistant VKC.

Background: Vernal keratoconjunctivitis (VKC) is a chronic recurrent non-infectious
allergic disease that generally affects children and young adults. The present study was
conducted to assess efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis.
Materials & Methods:86 patients diagnosed with Vernalkeratoconjunctivitis (VKC) of both
genderswere enrolled. All were prescribed topical 0.05% cyclosporine 4 times a day.
Patients underwent complete ophthalmic examination and symptoms and signs and
intraocular pressure using non contact tonometer. The patients were evaluated at weeks 4,
8 and 12 after the initiation of therapy. Symptoms and signs before and after treatment,
during the four-week intervals, were recorded and scores between 0 and 3 were assigned.
Results: Out of 86 patients, males were 56 and females were 30. Median of symptoms score
at baseline was 11, at 4 weeks were 4, at 8 weeks were 5 and at 12 weeks were 4. Sign score
at baseline was 6, at 4 weeks were 4, at 8 weeks were 3 and at 12 weeks were 3. The
difference was significant (P< 0.05).
Conclusion: Topical cyclosporine 0.05% help to reduce corticosteroid usage, is an effective
and safe alternative for the treatment of resistant VKC.

Background: Vernal keratoconjunctivitis (VKC) is a chronic recurrent non-infectious allergic disease that generally affects children and young adults. The present study was conducted to assess efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis. Materials & Methods:86 patients diagnosed with Vernalkeratoconjunctivitis (VKC) of both genderswere enrolled. All were prescribed topical 0.05% cyclosporine 4 times a day. Patients underwent complete ophthalmic examination and symptoms and signs and intraocular pressure using non contact tonometer. The patients were evaluated at weeks 4, 8 and 12 after the initiation of therapy. Symptoms and signs before and after treatment, during the four-week intervals, were recorded and scores between 0 and 3 were assigned. Results: Out of 86 patients, males were 56 and females were 30. Median of symptoms score at baseline was 11, at 4 weeks were 4, at 8 weeks were 5 and at 12 weeks were 4. Sign score at baseline was 6, at 4 weeks were 4, at 8 weeks were 3 and at 12 weeks were 3. The difference was significant (P< 0.05). Conclusion: Topical cyclosporine 0.05% help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC.